Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus WT1 dendritic cell vaccine with platinum/pemetrexed in first-line epithelioid malignant pleural mesothelioma
2024-515293-27-00Phase 2Authorised
- Sponsor
- Antwerp University Hospital
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and WT1 LAMP mRNA dendritic cell vaccine in pleural mesothelioma, sponsored by Antwerp University Hospital. Primary endpoints: Feasibility, Safety - incidence of treatment-related AEs/SAEs and 1 more. Planned start Nov 2024; status: authorised.
02
Drugs
atezolizumabWT1 LAMP mRNA dendritic cell vaccine
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2024-515293-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515293-27-00.